Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerClinical Trial

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551566

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551566

Oncology Clinical Trials

PUBLISHED:
PAGES: 283 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Oncology Clinical Trials Market to Reach US$15.7 Billion by 2030

The global market for Oncology Clinical Trials estimated at US$11.2 Billion in the year 2023, is expected to reach US$15.7 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Phase I Clinical Trials, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$7.9 Billion by the end of the analysis period. Growth in the Phase II Clinical Trials segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 8.4% CAGR

The Oncology Clinical Trials market in the U.S. is estimated at US$3.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Oncology Clinical Trials Market - Key Trends and Drivers Summarized

Why Are Oncology Clinical Trials Crucial in the Fight Against Cancer?

Oncology clinical trials are at the forefront of cancer research, but why are they so crucial in the fight against this complex disease? Clinical trials in oncology are essential because they are the primary means by which new treatments are tested for safety, efficacy, and overall benefit to patients. These trials pave the way for the development of innovative therapies, including targeted drugs, immunotherapies, and combination treatments that can provide better outcomes than existing options. Given the heterogeneous nature of cancer, with its many subtypes and varied genetic mutations, oncology clinical trials are designed to explore how different treatments work across diverse patient populations. This is particularly important as personalized medicine becomes more prevalent, where treatments are tailored to the individual’s genetic makeup and specific characteristics of their cancer. The data generated from these trials not only informs clinical practice but also helps shape future research directions. As cancer remains one of the leading causes of death worldwide, the ongoing efforts in clinical trials are vital in finding more effective treatments and ultimately improving survival rates and quality of life for patients.

How Do Innovations in Oncology Clinical Trials Impact Patient Care?

The landscape of oncology clinical trials is rapidly evolving, but how do these innovations impact patient care? One of the most significant advancements is the incorporation of precision medicine into trial designs. Precision medicine aims to tailor treatments based on the genetic profiles of individual tumors, and this approach has been integrated into clinical trials to identify which patients are most likely to benefit from specific therapies. This not only improves the likelihood of success in trials but also ensures that patients receive the most effective treatments with fewer side effects. Another innovation is the use of adaptive trial designs, which allow modifications to the trial protocols based on interim results. This flexibility can accelerate the development of promising therapies by allowing researchers to focus resources on the most effective treatments early in the process. Additionally, the rise of decentralized and virtual clinical trials, which utilize digital health technologies and telemedicine, has made it easier for patients to participate in studies, particularly those in remote or underserved areas. This has broadened the reach of oncology trials, ensuring more diverse patient populations are represented. These innovations are transforming how clinical trials are conducted, making them more efficient, patient-centered, and ultimately leading to better outcomes in cancer care.

What Are the Latest Trends Shaping the Future of Oncology Clinical Trials?

Oncology clinical trials are being shaped by several key trends, but what are the latest developments that could define their future? One of the most prominent trends is the increasing focus on immuno-oncology, where clinical trials are exploring therapies that harness the immune system to fight cancer. Immunotherapies, such as checkpoint inhibitors and CAR-T cell therapy, have shown remarkable results in certain cancers, leading to a surge in clinical trials testing these approaches in various tumor types. Another significant trend is the growing importance of biomarker-driven trials, which aim to identify biological markers that predict how well a patient will respond to a particular treatment. These trials are crucial in the era of personalized medicine, as they help stratify patients and ensure that those most likely to benefit from a treatment are the ones who receive it. The use of real-world evidence (RWE) in oncology trials is also gaining traction, with data from electronic health records, patient registries, and other sources being used to complement traditional clinical trial data. This approach provides a more comprehensive understanding of how treatments perform in everyday clinical practice. Additionally, the integration of artificial intelligence (AI) and machine learning in clinical trial design and data analysis is streamlining the process, enabling faster and more accurate identification of potential therapies. These trends are driving significant changes in how oncology trials are conducted, with a clear emphasis on precision, efficiency, and patient-centricity.

What Factors Are Driving the Growth in the Oncology Clinical Trials Market?

The growth in the oncology clinical trials market is driven by several factors, reflecting the increasing demand for innovative cancer treatments and the evolving landscape of cancer research. One of the primary drivers is the rapid advancement in genomics and molecular biology, which has enabled the development of targeted therapies that require rigorous clinical testing. The rise of personalized medicine, where treatments are tailored to the genetic profile of an individual’s cancer, has created a need for more specialized and complex trials, contributing to market growth. Another significant factor is the increasing incidence of cancer worldwide, which has led to a greater focus on finding effective treatments, thereby driving the demand for clinical trials. The expansion of global clinical trial networks and collaborations between pharmaceutical companies, research institutions, and healthcare providers has also played a crucial role in facilitating more trials across different regions. Furthermore, the growing acceptance and integration of digital technologies, such as telemedicine and electronic data capture, have streamlined trial processes, making it easier to recruit participants and manage trials remotely. The involvement of patient advocacy groups in trial design and patient recruitment has also enhanced trial participation and ensured that patient needs are prioritized. Together, these factors are fueling the robust growth of the oncology clinical trials market, positioning it as a critical component of the future of cancer treatment.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • AstraZeneca PLC
  • Caidya(TM)
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • ICON Plc
  • Medpace, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novotech
  • PAREXEL International Corporation
  • Pfizer, Inc.
  • PRA Health Sciences
  • Syneos Health
Show more
Product Code: MCP26686

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Oncology Clinical Trials - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Cancer Incidence Spurs Growth in Oncology Clinical Trials
    • Advancements in Precision Medicine Expand Addressable Market Opportunity for Targeted Cancer Therapies
    • Increased Focus on Immuno-Oncology Strengthens Business Case for Novel Clinical Trials
    • Adoption of Adaptive Trial Designs Drives Efficiency and Accelerates Drug Development
    • Integration of Digital Health Tools and AI Generates Demand for Smarter Oncology Clinical Trials
    • Growing Patient Advocacy and Engagement Throws the Spotlight on Patient-Centric Trial Models
    • Rise of Decentralized and Virtual Trials Expands Access and Participation in Oncology Research
    • Innovations in Biomarker Discovery Drive Adoption of Personalized Oncology Trial Approaches
    • Global Expansion of Oncology Research Networks Creates New Opportunities for Multinational Trials
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oncology Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oncology Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oncology Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Oncology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Phase I Clinical Trails by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Phase I Clinical Trails by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Phase I Clinical Trails by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phase II Clinical Trails by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Phase II Clinical Trails by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Phase II Clinical Trails by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Phase III Clinical Trails by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Phase III Clinical Trails by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Phase III Clinical Trails by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Phase IV Clinical Trails by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Phase IV Clinical Trails by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Phase IV Clinical Trails by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Interventional Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Interventional Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Interventional Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Observational Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Observational Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Observational Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Expanded Access Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Expanded Access Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Expanded Access Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • JAPAN
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • CHINA
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • EUROPE
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Oncology Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Oncology Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Oncology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • FRANCE
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • GERMANY
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Oncology Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Oncology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • INDIA
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Oncology Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Oncology Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Oncology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Oncology Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Oncology Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Oncology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030
  • AFRICA
    • Oncology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Oncology Clinical Trials by Phase Type - Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Oncology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I Clinical Trails, Phase II Clinical Trails, Phase III Clinical Trails and Phase IV Clinical Trails for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Oncology Clinical Trials by Study Type - Interventional Studies, Observational Studies and Expanded Access Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Oncology Clinical Trials by Study Type - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!